Led · Debt Financing · Jan 2026

Founded in 2019, Sokin provides businesses with access to more than 70 currencies for transfers and exchanges, the ability to hold balances in 26 currencies via multi-currency IBAN and local accounts, and transaction capabilities across 170+ countries. Its platform serves both direct business clients and partners who embed Sokin’s infrastructure into their own offerings, addressing demand for integrated, end-to-end payment workflows. The company has maintained 100% year-on-year revenue growth while remaining profitable and was named one of The Sunday Times’ fastest-growing technology companies. Headquartered in the United Kingdom, Sokin operates additional offices in Australia, the United States, Canada, the United Arab Emirates, Singapore, Mexico, Norway, and India. Recent product roadmaps include expanding embedded payments features and scaling global infrastructure. Management reports that the fresh capital lowers borrowing costs, positions Sokin to secure additional regional licenses, and supports further geographic expansion across North America, Asia, the Middle East, and South America. The firm services clients across diverse verticals, from freight and logistics to Premier League football clubs.

Led · Debt Financing · Jul 2023

Headspace provides evidence-based mindfulness and mental health tools through its flagship direct-to-consumer app and combines that experience with enterprise offerings that include coaching, therapy, psychiatry and EAP services. The company serves over 4,000 employers across 200 countries and works with an ecosystem of health plans and partners, including large plans like Cigna and organizations such as Accolade, Virgin Pulse and Sequoia. Proceeds from the financing are intended to support expansion of Headspace's mental health platform and to allow the company to be opportunistic in investing where it sees market need. Management stated the financing positions Headspace to expand its enterprise EAP offering and accelerate bringing services to more health plans and directly to consumers in the coming year. The business emphasizes scaling mental health support using technology and has decades of expertise and a global user base. Armentum Partners served as financial advisor to Headspace on the transaction. Headspace operates a consumer mindfulness and meditation app and sells on-the-job mental wellness tools for employers and healthcare practitioners. The company is pursuing clinical validation for mindfulness with a pipeline of about 70 clinical studies in partnership with academic institutions including Carnegie Mellon, UCSF and Stanford. Headspace says its app has been downloaded more than 62 million times across 190 countries, has over 2 million paid subscribers, and is used by more than 600 businesses. The new financing will be directed toward clinical research, expanding business and healthcare sales, and international growth — the company already offers German and French versions of the app. Headspace has appointed former Apple executive Renate Nyborg to lead its European expansion as it competes with rivals like Calm. CEO and co-founder Richard Pierson highlighted the company’s focus on applying mindfulness to broader areas of members’ lives and on delivering better access through employers and healthcare providers. Headspace offers a subscription meditation app and related mindfulness content. The company is cash-flow positive and reports many users pay a $96 annual subscription; its app has been downloaded more than 16 million times and revenue is stated as above $10 million and possibly above $50 million. Management recently installed co-founder Rob Pierson as CEO, who made staff reductions and hired a chief business officer. Headspace plans to use new capital to expand internationally and translate its app into more languages. The company also intends to broaden its content into nutrition, exercise, science and kids programming and to pursue larger corporate partnerships to grow enterprise sales. Headspace is a guided meditation and mindfulness startup offering guided meditation sessions via app and web. Its core product includes a free 'Take 10' ten-minute program and paid subscription plans that provide access to hundreds of hours of content on topics such as stress, creativity, relationships and happiness. Subscription pricing noted in the article includes monthly ($12.95), yearly ($7.99/month), two-year ($6.24/month) and a lifetime option ($419.95). Headspace reports about 3 million users in over 150 countries but does not disclose detailed engagement metrics. Co-founder Andy Puddicombe, a former monk who leads the guided meditations, is cited as contributing to the service’s authenticity. The app is available on iOS, Android and the web, and the company plans to expand content and hire more engineers and content marketers; Headspace is based in London and Venice, California.

Participated · Debt Financing · Nov 2022

Renibus Therapeutics is a clinical-stage biopharmaceutical company focused on preventing and treating cardio-renal and metabolic diseases. Its lead candidate, RBT-1 (stannic protoporfin/iron sucrose), is being developed as a preconditioning agent that induces anti-inflammatory, antioxidant, and iron-scavenging pathways and is initially studied in cardiac surgery patients. Renibus completed a randomized, double-blind, multi-center, placebo-controlled Phase 2 study of RBT-1 in February 2023 and announced positive final results in May 2023. RBT-1 received Breakthrough Therapy designation from the U.S. FDA in June 2023, and Renibus reached agreement with the FDA on the Phase 3 program in July 2023. The company intends to advance RBT-1 into a pivotal Phase 3 trial to reduce postoperative complications following cardiothoracic surgery and to prepare for an NDA filing. Renibus recently closed a Series B financing extension that brings total proceeds to $72 million to support the Phase 3 program and selective funding of additional pipeline programs. Renibus Therapeutics, based in Southlake, TX, is a clinical-stage biopharmaceutical company led by Co-CEOs Frank Stonebanks and D. Jeff Keyser. The company has developed a portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Its lead program, RBT-1, is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways and is being advanced for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-2 is an antioxidant and anti-fibrotic candidate with preclinical data suggesting potential to reduce CKD progression. RBT-3 is a low molecular weight iron nanoparticle aimed at rapidly resolving anemia and reducing cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporphyrin) is an anti-inflammatory and antioxidant drug with reported broad-spectrum antiviral properties and was investigated in a 42-patient Phase 2 randomized, placebo-controlled trial in high-risk COVID-19 patients. Renibus Therapeutics develops a portfolio of products that activate multiple cytoprotective pathways to prevent disease progression and protect organs in cardiorenal diseases. Its lead program, RBT-1 (SnPP/FeS), is a potent inducer of Nrf2, IL-10, and ferritin and is in Phase 2 development in cardiac surgery, with plans to enter a Phase 3 registration study for its lead indication to reduce postoperative complications after cardiothoracic surgery. RBT-2 (tetrahydrocurmin) is an antioxidant and anti-fibrotic intended to inhibit CKD progression and is slated for IND-enabling and clinical development in 2023. RBT-3 (FeS), a low molecular weight iron nanoparticle and component of RBT-1, is targeted at reducing cisplatin-induced nephrotoxicity and will enter clinical development in 2023. RBT-9 (SnPP), the other component of RBT-1, has anti-inflammatory, antioxidant, and antiviral properties and was studied in a 42-patient Phase 2 RCT in COVID pneumonia, where it reportedly reduced hospital length of stay by ~70%. The company, led by Chairman and CEO Frank Stonebanks and based in South Lake, Texas, recently secured bridge financing to support these development plans. Renibus Therapeutics is a Southlake, TX–based clinical-stage biotech focused on advancing the cardiorenal disease treatment paradigm by preventing and treating kidney disease. Its portfolio includes RBT-1 (prevention of acute kidney injury), RBT-2 (treatment of chronic kidney disease) and RBT-3 (treatment of iron deficiency anemia and platinum-based kidney toxicity). RBT-1 is in a large (126-patient), randomized, double-blind study in AKI in a cardiac surgery setting. RBT-2 is scheduled to begin Phase I later this year. RBT-3 may commence Phase III development in Q3 2022 and is described as having a differentiated profile versus the current standard of care. The company completed a Series A financing that closed at $35M and intends to use the funds to advance its pipeline and lead candidates.

Led · Debt Financing · Jul 2022

RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a therapy that uses a single radiotracer injection to generate real-time signals to guide autonomous radiotherapy. SCINTIX is delivered via the RefleXion X1, a dual-treatment modality platform that also provides image-guided radiotherapy. The company positions SCINTIX to treat all stages of indicated solid tumor cancers, including metastatic disease, by addressing targeting and motion-management barriers. SCINTIX has received FDA De Novo marketing authorization and a Breakthrough Device designation for lung tumors, and is indicated for FDG-guided treatment of lung and bone tumors. The X1 platform is also cleared for image-guided external-beam radiotherapy for solid tumors located anywhere in the body. RefleXion plans to use proceeds from its recent equity raise to extend commercialization of SCINTIX therapy. RefleXion Medical is a privately held therapeutic oncology company developing biology-guided radiotherapy (BgRT) and commercializing the RefleXion X1 radiotherapy platform. The X1 is cleared for delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is developing BgRT, which uses PET imaging to enable tumors to continuously signal their location and synchronize that data with a linear accelerator. RefleXion is pursuing commercialization of X1 while preparing BgRT for regulatory review and future clinical use. The company is building a radiopharmaceutical program and has a co-development agreement with Telix Pharmaceuticals to explore a PSMA-targeted PET tracer for use with BgRT. RefleXion recently hosted a cancer symposium with clinicians from 30 top U.S. cancer programs to support clinical engagement and adoption. RefleXion Medical is a privately-held therapeutic oncology company developing biology-guided radiotherapy (BgRT) and the RefleXion X1 system to enable treatment of multiple tumors, including metastatic disease. The X1 is currently cleared for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), while BgRT is pending regulatory review and not commercially available. BgRT incorporates PET radiotracer imaging to continuously signal tumor location and synchronizes those data with a linear accelerator to direct radiotherapy with subsecond latency. The company has positioned BgRT to expand radiotherapy to late-stage cancers and the technology recently received FDA Breakthrough Device designation for use in lung tumors. RefleXion reports delivering nearly 2,000 patient treatments, completing a feasibility study, securing an additional radiopharmaceutical agreement, and expanding its commercial footprint. The $80 million financing will fund further development and commercialization of the BgRT platform. RefleXion develops the RefleXion X1 system and is pioneering biology-guided radiotherapy (BgRT), which uses PET imaging data to enable tumors to continuously signal their location and allow radiotherapy with sub-second latency. The X1 is currently cleared for delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT); the BgRT capability requires additional 510(k) clearance and is not yet available for sale. The company says BgRT is designed to scale radiotherapy from one or two tumors to all visible tumors, including those that move rapidly due to breathing or digestion, in the same treatment session. Commercialization efforts began in mid-2020 and the company reports a promising market ramp since then. Financially, RefleXion completed a Series D financing that now totals $150 million, reflecting continued investor support as it approaches broader commercialization. The company is based in Hayward, Calif., and emphasizes partnering with pharmaceutical agents and international investors to establish a global footprint. RefleXion develops the RefleXion X1, a biology-guided radiotherapy (BgRT) system designed to treat multiple visible tumors, including those that move due to breathing or digestion, within the same session. The BgRT approach incorporates PET imaging data so tumors continuously signal their location and the system synchronizes those data with a linear accelerator to deliver radiotherapy with subsecond latency. The company recently received FDA clearance for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). RefleXion notes that the BgRT capability requires a separate 510(k) clearance and is not yet available for sale. The company has secured its first system order at a leading cancer center and is focused on scaling market and clinical adoption of the X1 platform. To support commercialization and validation of BgRT in practice, RefleXion closed a $100 million equity financing led by PSP Investments.

Led · Debt Financing · Jun 2022

Selux Diagnostics develops the Selux Next Generation Phenotyping (NGP) System, a rapid antibiotic susceptibility testing (AST) platform that can deliver same-day AST results. The company says the platform can provide single-platform rapid AST for both positive blood culture and isolated colonies following its third FDA 510(k) clearance on the direct-from-Positive Blood Culture Separator. Selux intends to use the additional funding to launch the next phase of commercialization of the NGP System within the United States. The company is led by CEO Steve Lufkin and aims to accelerate selection of personalized antimicrobial therapy for infectious disease patients to reduce overreliance on broad-spectrum antibiotics. The NGP program has been supported in whole or in part with federal funds from HHS, ASPR, and BARDA under contract HHSO100201800013C. Selux Diagnostics is focused on accelerating antibiotic susceptibility testing (AST) with its proprietary Next-Generation Phenotyping (NGP) platform to deliver actionable results days faster than current standards. The NGP platform aims to enable clinicians to provide personalized antimicrobial therapies within 24 hours, improving patient outcomes and reducing broad-spectrum antibiotic overuse. Selux describes the platform as meeting accuracy, throughput, and cost-effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems. The platform is an investigational device and the company is working with BARDA and other private investors to advance development. Selux says the work addresses the urgent global threat of antimicrobial resistance and is funded in part by federal BARDA/ASPR/HHS support. The company is Boston-based and described as five years old in the announcement. Selux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) rapid antimicrobial susceptibility testing platform. The NGP platform provides <24-hour personalized antimicrobial therapy results and enables same-shift susceptibility testing of up to 50 antibiotics in parallel through a high-throughput, fully automated system. Selux's platform combines novel biochemical assays with artificial intelligence to differentiate antibiotic-induced bacterial growth modes and accelerate targeted patient therapies. The company says proceeds from its recent financing will fund commercialization of NGP as it seeks to establish same-shift rapid AST as the new standard. Selux is five years old and positions its technology to shorten hospital stays, improve patient outcomes, and help combat antibiotic resistance. CEO Steve Lufkin described the partnership with Oxford as the next step in fighting the global crisis of antibiotic resistance. Selux Diagnostics develops a Phenotyping (NGP) rapid antimicrobial susceptibility testing platform that delivers automated AST results and enables same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform combines novel biochemical assays and artificial intelligence to differentiate antibiotic-induced bacterial growth modes. Selux aims to fast-track targeted patient therapies so patients can receive appropriate treatments on day one. The company is led by CEO Steve Lufkin and is based in Boston, MA. Selux has regulatory progress including FDA Breakthrough Device Designation for NGP in September 2021 for positive blood culture and sterile body fluid indications, and received a $2.8M NIH award in October 2021 to support commercialization. The company plans to use new funding to support the U.S. commercial launch of NGP. Selux Diagnostics is developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing (AST) that aims to provide targeted therapy results in under 24 hours. The proprietary NGP technology delivers rapid AST results from cultured isolates with a broad antibiotic menu while targeting the accuracy, throughput, and cost-effectiveness required by clinical microbiology laboratories and integrated healthcare systems. Selux completed its first clinical trial, which confirmed the platform's ability to accurately provide rapid AST within the same shift, and the company plans to submit those results to the U.S. Food and Drug Administration as the next step toward commercialization. The platform is investigational and has been funded in whole or in part by BARDA under Contract No. HHSO100201800013C. Selux says it will use the funding to continue implementing its microbiology roadmap and accelerate product development to speed time to targeted antibiotic treatment. The five-year-old company is based in Boston, MA.